Abstract:Macroautophagy/autophagy is an evolutionarily conserved pathway responsible for clearing cytosolic aggregated proteins, damaged organelles or invading microorganisms. Dysfunctional autophagy leads to pathological accumulation of the cargo, which has been linked to a range of human diseases, including neurodegenerative diseases, infectious and autoimmune diseases and various forms of cancer. Cumulative work in animal models, application of genetic tools and pharmacologically active compounds, has suggested the potential therapeutic value of autophagy modulation in disease, as diverse as Huntington, Salmonella infection, or pancreatic cancer. Autophagy activation versus inhibition strategies are being explored, while the role of autophagy in pathophysiology is being studied in parallel. However, the progress of preclinical and clinical development of autophagy modulators has been greatly hampered by the paucity of selective pharmacological agents and biomarkers to dissect their precise impact on various forms of autophagy and cellular responses. Here, we summarize established and new strategies in autophagy-related drug discovery and indicate a path toward establishing a more efficient discovery of autophagy-selective pharmacological agents. With this knowledge at hand, modern concepts for therapeutic exploitation of autophagy might become more plausible.Abbreviations: ALS: amyotrophic lateral sclerosis; AMPK: AMP-activated protein kinase; ATG: autophagy-related gene; AUTAC: autophagy-targeting chimera; CNS: central nervous system; CQ: chloroquine; GABARAP: gamma-aminobutyric acid type A receptor-associated protein; HCQ: hydroxychloroquine; LYTAC: lysosome targeting chimera; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NDD: neurodegenerative disease; PDAC: pancreatic ductal adenocarcinoma; PE: phosphatidylethanolamine; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: class III phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol 3-phosphate; PROTAC: proteolysis-targeting chimera; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SQSTM1/p62: sequestosome 1; ULK1: unc-51 like autophagy activating kinase 1.

Natural Activators of Autophagy

Synthetic Activators of Autophagy

Progress on the Autophagic Regulators and Receptors in Plants.

Natural Autophagy Activators to Fight Age-Related Diseases

Natural autophagy modulators in non-communicable diseases: from autophagy mechanisms to therapeutic potential

Autophagy Regulators As Potential Cancer Therapeutic Agents: A Review

Targeting autophagy using natural compounds for cancer prevention and therapy

Targeting autophagy with small-molecule activators for potential therapeutic purposes

Pharmaceutical Agents for Targeting Autophagy and Their Applications in Clinics

New Visions on Natural Products and Cancer Therapy: Autophagy and Related Regulatory Pathways

Targeting Autophagy with Natural Products as a Potential Therapeutic Approach for Cancer

Targeting Autophagy with Natural Compounds in Cancer: A Renewed Perspective from Molecular Mechanisms to Targeted Therapy

Targeting autophagy in ethnomedicine against human diseases

Current Status of Autophagy Enhancers in Metabolic Disorders and Other Diseases

Autophagy And Cardiac Diseases: Therapeutic Potential Of Natural Products

Natural Product Regulates Autophagy in Cancer.

Identification of Dietary Phytochemicals Capable of Enhancing the Autophagy Flux in HeLa and Caco-2 Human Cell Lines

Natural Compounds Targeting the Autophagy Pathway in the Treatment of Colorectal Cancer

The Participation of Non-Canonical Autophagic Proteins in the Autophagy Process and Their Potential As Therapeutic Targets

Targeting autophagy in disease: established and new strategies

Autophagy in healthy aging and disease